Summary & Overview
HCPCS Level II J0295: Injection, Ampicillin/Sulbactam, 1.5 gm
HCPCS Level II code J0295 denotes the injectable combination of ampicillin sodium and sulbactam sodium, billed per 1.5 gram unit. This antimicrobial is used for systemic infections requiring parenteral beta-lactam/beta-lactamase inhibitor therapy and is relevant across inpatient, emergency, and outpatient infusion settings. Accurate coding for parenteral antibiotics affects hospital and clinic drug billing, drug utilization tracking, and payer reimbursement processes nationally.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks on code usage and payment patterns, guidance on clinical and billing contexts for injectable antibiotic administration, and summaries of common modifiers and documentation points that influence claim adjudication. The publication outlines where J0295 is typically billed (hospital outpatient departments, inpatient settings, emergency departments, and infusion/clinic sites) and clarifies the unit definition (per 1.5 gm).
This summary also highlights policy considerations that commonly affect injectable drug billing, such as unit reporting, drug wastage rules, and site-of-care impacts on payment, and points to clinical scenarios where ampicillin/sulbactam is commonly indicated. Data not available in the input is noted where specific benchmark values, associated taxonomies, and ICD-10 diagnoses would normally be provided.
Billing Code Overview
HCPCS Level II code J0295 represents an injection formulation of ampicillin sodium combined with sulbactam sodium, billed per 1.5 gram unit. This code describes the drug product administered as an injectable antimicrobial.
Service type: Drug administration (injectable antibiotic)
Typical site of service: Hospital outpatient department, inpatient facility, emergency department, or clinic setting where parenteral antibiotics are administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an emergency department or outpatient infusion clinic with a moderate to severe bacterial infection such as complicated urinary tract infection, intra-abdominal infection, skin and soft tissue infection, or community-acquired pneumonia where empiric or targeted intravenous beta-lactam/beta-lactamase inhibitor therapy is indicated. The clinician orders J0295 (injection, ampicillin sodium/sulbactam sodium, per 1.5 gm) to be administered intravenously or by deep intramuscular injection depending on venous access and clinical urgency. The workflow includes documented indication and informed consent as needed, verification of allergies (particularly to penicillins), preparation and reconstitution of the 1.5 gm vial, administration by a registered nurse, monitoring for infusion reactions, and documentation of dose, route, time, lot number, and site of administration. Subsequent clinical evaluation and culture results guide continuation, escalation, or de-escalation of therapy; additional supportive orders may include fluids, antipyretics, and laboratory monitoring such as basic metabolic panel and repeat cultures when clinically appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered to any patient | When a portion of a single-use vial is discarded after preparation and documentation of discarded amount is required |
JZ | No drug administered, zero drug waste | When a prepared dose is administered with no wastage |
59 | Distinct procedural service | When J0295 is billed in the same encounter as another service that is distinct and separate (use per payer guidance) |
25 | Significant, separately identifiable E/M service | When a separate evaluation and management visit is performed on the same day as administration |
22 | Increased procedural services — unusual procedural services | Rarely used; when additional work beyond typical administration is documented (e.g., complex access or monitoring) |
52 | Reduced services | When less than the full service is performed (use per payer rules) |
53 | Discontinued procedure | When preparation started but administration was discontinued due to patient reaction or other clinical reason |
76 | Repeat procedure by same provider (Not in provided list) | Data not available in the input. |
90 | Reference (outside) laboratory (Note: typically not applicable to J-codes) | When a lab test related to therapy is performed by an outside lab |
62 | Two surgeons (Not typically applicable) | When two qualified practitioners are involved (rare for drug administration) |
QX | Rendering provider NPI not enrolled in Medicare (Cert. requirements) | When a supervising nurse practitioner/PA performs service under specified supervisory rules |
RT | Right side (Not applicable) | Not typically applicable to systemic drug administration |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207Q00000X | Infectious Disease Specialist | Often directs antibiotic selection for complicated infections |
207L00000X | Emergency Medicine Physician | Commonly orders and initiates J0295 in ED settings |
364A00000X | Hospitalist/Internal Medicine | Manages inpatient administration and continuation |
163W00000X | Registered Nurse (R.N.) | Prepares and administers IV medication and documents administration |
207K00000X | Family Medicine Physician | Prescribes and oversees outpatient or observation-administered doses |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
J18.9 | Pneumonia, unspecified organism | Empiric IV beta-lactam/beta-lactamase inhibitor therapy may be used for moderate to severe community-acquired pneumonia |
N39.0 | Urinary tract infection, site not specified | Complicated or severe UTIs may require IV ampicillin/sulbactam |
K35.80 | Acute appendicitis without perforation or abscess | Perioperative or preoperative IV broad-spectrum coverage may include J0295 |
K65.9 | Peritonitis, unspecified | Intra-abdominal infections often require IV combination antibiotics |
L03.90 | Cellulitis, unspecified | Skin and soft tissue infections frequently treated with IV beta-lactam/beta-lactamase regimens |
A41.9 | Sepsis, unspecified organism | Systemic infections/sepsis often necessitate empiric broad IV antibiotics including ampicillin/sulbactam |
B95.61 | Methicillin susceptible Staphylococcus aureus as the cause of diseases classified elsewhere | Identifying causative organisms guides continuation or change of J0295 therapy |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | Used when J0295 is administered as part of an IV infusion lasting up to 1 hour and billed per infusion encounter |
96373 | Therapeutic, prophylactic, or diagnostic injection (single or initial substance/drug) | Used to report initial intramuscular or subcutaneous injection administration of a drug like J0295 when applicable |
96374 | Therapeutic, prophylactic, or diagnostic injection (each additional sequential intravenous push of a new substance/drug) | Used for additional different injectable drugs given during the same encounter |
36415 | Collection of venous blood by venipuncture | Commonly performed for cultures and labs before or during antibiotic therapy |
99406 | Smoking and tobacco-use cessation counseling (Not directly related) | Data not available in the input. |